| Methods |
4‐week placebo run‐in; inclusion criteria= 1) sitting DBP=95‐114 mm Hg and sitting SBP</=200mm Hg during 2 weeks immediately prior to randomization, and on day 0, the first day of active treatment, with variation in DBP of not more than 10 mm Hg between the last week of run‐in phase and day 0, and 2) mean daytime (0600‐2159h) DBP>/=85 mm Hg by ambulatory BP monitoring on day immediately preceding randomization; 8‐week double‐blind treatment |
| Participants |
Enalapril 20 mg once daily: n=53(35 males,18 females); mean age=52.2(10.3) years; baseline sitting SBP=165.2(14.5) mm Hg, DBP=101.1(4.4) mm Hg; baseline HR=78.0(7.3) bpm;
Placebo: n=50(29 males,21 females); mean age=53.7(8.7) years; baseline sitting SBP=162.8(14.5) mm Hg, DBP=99.9(3.9) mm Hg; baseline HR=76.6(8.8) bpm |
| Interventions |
Enalapril 20 mg once daily,
Placebo;
administered in morning (8.00+/‐2 h) |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP and SD reported, BP data from Table II, p. 169; Jadad score=4; funding source= Solvay Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
